We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · January 20, 2022

Outcomes in Patients With MDS Undergoing Allo-HSCT Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors

JAMA Oncology

 

Additional Info

JAMA Oncology
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors
JAMA Oncol 2022 Jan 13;[EPub Ahead of Print], GS Guru Murthy, S Kim, ZH Hu, N Estrada-Merly, MB Abid, M Aljurf, U Bacher, SM Badawy, A Beitinjaneh, C Bredeson, JY Cahn, J Cerny, MA Diaz Perez, N Farhadfar, RP Gale, S Ganguly, U Gergis, GC Hildebrandt, MR Grunwald, S Hashmi, NM Hossain, M Kalaycio, RT Kamble, MA Kharfan-Dabaja, BK Hamilton, HM Lazarus, J Liesveld, M Litzow, DI Marks, HS Murthy, S Nathan, A Nazha, T Nishihori, SS Patel, A Pawarode, D Rizzieri, B Savani, S Seo, M Solh, C Ustun, M van der Poel, LF Verdonck, R Vij, B Wirk, B Oran, R Nakamura, B Scott, W Saber

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading